Compare Organon & Co. Common Stock (OGN) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Transocean Ltd — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Transocean Ltd trades at $5.58 (market cap $6.31B). The key difference: Transocean Ltd is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Transocean Ltd for 18 Days on average.
| OGN | RIG | |
|---|---|---|
Market Cap | $3.62B | $6.31B |
Volume | 2,892,999 | 37,551,905 |
Sector | Health | Energy |
52-Week High | $13.81 | $7.58 |
52-Week Low | $5.70 | $3.23 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $11.04B | $10.92B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Transocean (RIG) trades at $5.65, up 0.89% today, with a bullish technical signal from moving averages. The company shows mixed fundamentals with strong revenue growth to $4.1B in 2026 but persistent net losses. Recent contract wins including an $80M Equatorial Guinea deal and DOJ approval for the $5.8B Valaris acquisition provide positive catalysts. Cash flow improvement is notable with operating cash flow reaching $995M in 2026.
RIG presents a speculative opportunity driven by offshore cycle strength and deleveraging potential, but high debt levels and negative profitability pose significant risks. Analyst consensus is divided with 39% buy ratings, reflecting optimism about contract backlog versus concerns about execution and financial leverage. The stock's upside depends on successful debt reduction and sustained offshore drilling demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
